Sarepta Therapeutics, Inc. (LON:0L35)

Market Cap	8.03B
Revenue (ttm)	1.22B
Net Income (ttm)	90.91M
Shares Out	n/a
EPS (ttm)	0.91
PE Ratio	88.34
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,261
Average Volume	986
Open	109.37
Previous Close	108.99
Day's Range	106.30 - 109.80
52-Week Range	55.68 - 155.48
Beta	0.75
RSI	37.60
Earnings Date	Feb 28, 2025

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1980
• Employees: 1,314
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0L35

Financial Performance

In 2023, Sarepta Therapeutics's revenue was $1.24 billion, an increase of 33.26% compared to the previous year's $933.01 million. Losses were -$535.98 million, -23.81% less than in 2022.

Financial numbers in USD